Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 876–900 of 3,166 studies of type cohort or longitudinal study (page 36 of 127) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

This list as a page: Cohort or longitudinal study in the library →

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Amyotrophic lateral sclerosis (ALS) is a multi-system disease characterized primarily by progressive muscle weakness. 2 key findings →

Design: longitudinal study Participants: 327 Evidence: moderate

Most people's cognitive abilities decline with age, with significant and partly genetically driven, individual differences in rate of change. 3 key findings →

Design: longitudinal study Participants: 1,087 Evidence: moderate

In the Asan cohort, after adjusting for age and sex, p-tau181 (AUC = 0.854) or APOE ε4 status (AUC = 0.769) distinguished Aβ status with high accuracy. 5 key findings →

Design: cohort study Evidence: moderate

In the South Korean study to prevent cognitive impairment and protect BRAIN health through lifestyle intervention in at-risk elderly people (SUPERBRAIN), we evaluated the impact of a 24-week facility-based multidomain intervention (FMI) and home-based MI (HMI) on white matter integrity. 3 key findings →

Design: longitudinal study Participants: 152 Evidence: moderate

Dual Sensory Impairment and Cognitive Impairment in the Korean Longitudinal Elderly Cohort

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2021-04-07

At baseline, DSI was significantly associated with increased dementia prevalence compared to normal sensory function (odds ratio [OR] 2.17, 95% confidence interval [CI] 1.17-4.02), but SSI was not (OR 1.27, 95% CI 0.66-2.41). 4 key findings →

Design: cohort study Evidence: moderate

Daily driving is a multi-faceted, real-world, behavioral measure of cognitive functioning requiring multiple cognitive domains working synergistically to complete this instrumental activity of daily living. 1 key finding →

Design: longitudinal study Participants: 186 Evidence: moderate

Higher chronic exposure to SO2 was associated with a faster decline in memory score, whereas chronic exposure to CO, NO2 , and PM10 were not associated with the rate of cognitive decline. 4 key findings →

Design: longitudinal study Participants: 269 Evidence: moderate

There is clinical overlap between presentations of dementia due to limbic-predominant age-related TDP-43 encephalopathy (LATE) and Alzheimer's disease. 4 key findings →

Design: longitudinal study Participants: 78 Evidence: moderate

There were 11.8 transitions to a nursing home per 100 person-years among older adults who resided in an assisted living facility with a dementia care program, compared with 20.5 transitions to a nursing home per 100 person-years among older adults who resided in an assisted living facility without a dementia care program. 4 key findings →

Design: cohort study Participants: 977 Evidence: moderate

Traumatic Brain Injury, Seizures, and Cognitive Impairment Among Older Adults

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA network open 2024-08-01

Among the cohort of 7180 older adults (median age, 74 years [range, 65-102 years]; 4729 women [65.9%]), 1036 were African American or Black (14.4%), 21 were American Indian or Alaska Native (0.3%), 143 were Asian (2.0%), 332 were Hispanic (4.6%), and 5648 were non-Hispanic White (78.7%); the median educational level was 16.0 years (range, 1.0-29.0 years). 5 key findings →

Design: cohort study Evidence: moderate

ϵ4 prevalence in Black (46%) and White participants (46%) was almost double that of Latino participants (24%). ϵ4 was associated with poorer baseline episodic memory only in White participants (p = .001), but had a moderately strong association with episodic memory change across all racial/ethnic groups (Blacks= -.061 SD/year, Latinos = -.055,Whites= -.055). ϵ4 association with semantic memory change was strongest in White participants (-.071), intermediate in Latino participants (-.041), and weakest in Black participants (-.022). 4 key findings →

Design: longitudinal study Participants: 297 Evidence: moderate

Nocturnal hypoxemia was related to greater decline on the 3 MS . 5 key findings →

Design: longitudinal study Participants: 2,636 Evidence: moderate

Plasma p-tau217 and cortical FTP-SUVR were correlated (r = 0.61, p < .001), especially in temporo-parietal and dorsolateral frontal cortices. 4 key findings →

Design: longitudinal study Participants: 85 Evidence: moderate

APOEε4 potentiates amyloid β effects on longitudinal tau pathology

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Nature aging 2023-09-25

The mechanisms by which the apolipoprotein E ε4 (APOEε4) allele influences the pathophysiological progression of Alzheimer's disease (AD) are poorly understood. 2 key findings →

Design: longitudinal study Participants: 94 Evidence: moderate

We conclude that NPTX2 is a promising synapse-derived disease progression biomarker in genetic FTD. 3 key findings →

Design: longitudinal study Participants: 106 Evidence: moderate

APOE2 is associated with longevity independent of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 65 out of 100. eLife 2020-10-19

Combining human cohort data (over 24,000 people) with mouse models, this study found that carrying the APOE2 gene variant is linked to a longer lifespan, and that this benefit holds even when accounting for Alzheimer's diagnosis and brain pathology. 4 key findings →

Design: cohort Participants: 24,661 Evidence: moderate

By pooling two long-running community studies from the same region of Pennsylvania, researchers compared dementia rates across people born in different decades, from the 1900s to the 1940s. Each successively younger birth cohort had a substantially lower risk of developing dementia at a given age, with the youngest group's risk about a quarter of the oldest group's. This adds US evidence, independent of Framingham, that generational health improvements are lowering dementia risk. 4 key findings →

Design: cohort Participants: 3,010 Evidence: high

Tau accumulation and its spatial progression across the Alzheimer's disease spectrum

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Brain Communications 2024-02-07

This study tracked tau PET scans over time in over 800 people across the Alzheimer's spectrum and found that while tau broadly follows the classic 'Braak stage' spreading pattern, the exact regions affected vary a lot from person to person, especially as disease progresses. 4 key findings →

Design: cohort Participants: 832 Evidence: moderate

Alcohol consumption and risk of dementia: 23 year follow-up of Whitehall II cohort study

✓ Peer-reviewed alzhub usefulness score 65 out of 100. BMJ 2018-08-01

This 23-year study found a U-shaped relationship between alcohol and dementia risk: people who abstained from alcohol in midlife, as well as those who drank heavily (more than 14 units, about 14 standard drinks, per week), both had a higher risk of developing dementia than people who drank moderately. 4 key findings →

Design: cohort Participants: 9,087 Evidence: moderate

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed